Patients with refractory or relapsed disease at time of LMP-T infusion
| Patient . | Institution/ID . | Age/sex . | Diagnosis . | Days post-HSCT . | B or T cell . | Type of T cell/donor . | Total cell dose . | Response at 8 weeks postinfusion . | Outcome (length of follow-up) . | GVHD . | Toxicity possibly attributed to LMP-Ts . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20 | BCM/2145 | 15/F | CAEBV/HLH (EBV‐PCR+) | 76 | T | LMP1/2, MRD | 1.2 × 108/m2 | PD | Died of disease (2 mo) | None | None |
| 21 | BCM/1898 | 23/F | Hodgkin (EBER+, LMP+) | 1407 | B | LMP1/2, MUD | 2 × 107/m2 (fixed) | SD | Alive with disease (3+ years) | None | None |
| 22 | CNMC/P0085 | 18/F | NKTCL (EBER+) | 111 | T | LMP1/2, MUD | 2 × 107/m2 | PD | Died of disease (3 mo) | None | None |
| 23 | CNMC/P0107 | 10/F | CAEBV (EBV‐PCR+) | 40 | T | LMP1/2, MRD | 2 × 107/m2 | PD | Alive with disease (18 mo) | None | None |
| 24 | CNMC/P0132 | 19/M | HVLL (EBER+) | 63 | T | LMP1/2, MMRD | 4 × 107/m2 | PR | Died of HSCT complications (3 mo) | None | None |
| 25 | CNMC/P0126 | 14/F | CAEBV (EBV‐PCR+) | 35 | T | LMP1/2, MRD | 4 × 107/m2 | PD | Alive with EBV viremia (17 mo) | De novo, grade 1 skin | None |
| 26 | CNMC/P0130 | 2/F | EBV LPD/HLH (EBER+) | 117 | T | LMP1/2, MMRD | 4 × 107/m2 | PR | Died of disease (8 mo) | Reactivation | Grade 4 hepatic necrosis |
| Patient . | Institution/ID . | Age/sex . | Diagnosis . | Days post-HSCT . | B or T cell . | Type of T cell/donor . | Total cell dose . | Response at 8 weeks postinfusion . | Outcome (length of follow-up) . | GVHD . | Toxicity possibly attributed to LMP-Ts . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20 | BCM/2145 | 15/F | CAEBV/HLH (EBV‐PCR+) | 76 | T | LMP1/2, MRD | 1.2 × 108/m2 | PD | Died of disease (2 mo) | None | None |
| 21 | BCM/1898 | 23/F | Hodgkin (EBER+, LMP+) | 1407 | B | LMP1/2, MUD | 2 × 107/m2 (fixed) | SD | Alive with disease (3+ years) | None | None |
| 22 | CNMC/P0085 | 18/F | NKTCL (EBER+) | 111 | T | LMP1/2, MUD | 2 × 107/m2 | PD | Died of disease (3 mo) | None | None |
| 23 | CNMC/P0107 | 10/F | CAEBV (EBV‐PCR+) | 40 | T | LMP1/2, MRD | 2 × 107/m2 | PD | Alive with disease (18 mo) | None | None |
| 24 | CNMC/P0132 | 19/M | HVLL (EBER+) | 63 | T | LMP1/2, MMRD | 4 × 107/m2 | PR | Died of HSCT complications (3 mo) | None | None |
| 25 | CNMC/P0126 | 14/F | CAEBV (EBV‐PCR+) | 35 | T | LMP1/2, MRD | 4 × 107/m2 | PD | Alive with EBV viremia (17 mo) | De novo, grade 1 skin | None |
| 26 | CNMC/P0130 | 2/F | EBV LPD/HLH (EBER+) | 117 | T | LMP1/2, MMRD | 4 × 107/m2 | PR | Died of disease (8 mo) | Reactivation | Grade 4 hepatic necrosis |
BCM, Baylor College of Medicine; CNMC, Children’s National Medical Center; HLH, hemophagocytic lymphohistiocytosis; HVLL, hydroa vacciniforme-like lymphoma; MMRD, mismatched unrelated donor; MRD, matched related donor; MUD, matched unrelated donor; PCR, polymerase chain reaction; PD, progressive disease; PR, partial response; SD, stable disease.